AACR logo

More articles from Therapeutic Agents: Other Topics: Poster Presentations - Proffered Abstracts

Abstract LB-B28: Abietane natural products as novel therapeutics against solid tumors
Walter Lang, Taotao Ling, Jangsoon Lee, Naoto T. Ueno, Fatima Rivas

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) LB-B28; DOI: 10.1158/1535-7163.TARG-17-LB-B28
Abstract B139: Promising antitumor effects of SNX-5422 in combination with checkpoint inhibitors in an MC38 murine model
Yanmei Sun, Xirou Hu, Everardus Orlemans

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B139; DOI: 10.1158/1535-7163.TARG-17-B139
Abstract B123: A mesenchymal subset of cancers with elevated ZEB1 expression is sensitive to low doses of silver nanoparticles
Cale D. Fahrenholtz, Jessica Swanner, James Sears, Katherine Cook, Pierre-Alexandre Vidi, Ravi Singh

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B123; DOI: 10.1158/1535-7163.TARG-17-B123
Abstract B129: Development and preclinical assessment of a first-in-class small-molecule inhibitor of FLIP
Catherine A. Higgins, Joanna Majkut, Jennifer Fox, Luke Humphreys, Greti Espona Fiedler, Ray J. Boffey, Trevor R. Perrior, David Haigh, Timothy Harrison, Daniel B. Longley

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B129; DOI: 10.1158/1535-7163.TARG-17-B129
Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies
Katharine Yen, Zenon Konteatis, Zhihua Sui, Erin Artin, Lenny Dang, Kimberly Straley, Erica Tobin, Carl Campos, Hua Yang, Raj Nagaraja, Yue Chen, Hyeryun Kim, Camelia Gliser, Brandon Nicolay, Andrew Olaharski, Lee Silverman, Scott Biller, Shinsan M. Su, Ingo Mellinghoff, Janeta Popovici-Muller

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B126; DOI: 10.1158/1535-7163.TARG-17-B126
Abstract B138: Prognostic value of PTEN loss for second-line paclitaxel treatment efficacy in metastatic gastric cancer
Kyoo Hyun Kim, Jeong Hyun Jo, Sejung Park, Minkyu Jung, Woo Sun Kwon, Jee Hung Kim, Hyo Song Kim, Seung-Hoon Beom, Hyun Cheol Chung, Sun Young Rha

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B138; DOI: 10.1158/1535-7163.TARG-17-B138
Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP
Gavin Bennett, Mike Rigby, Bob Lutz, Peter Park, Nicholas Keen

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B135; DOI: 10.1158/1535-7163.TARG-17-B135
Abstract B141: Repurposing of ketorolac for the treatment of renal cell carcinoma (RCC)
Jeevan Deepak Ghosalkar, Siddhika Rajiv Raut, Mariamma Charles Thekkumpurath, Geena Malhotra, Kalpana Sanjay Joshi

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B141; DOI: 10.1158/1535-7163.TARG-17-B141
Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology
Neel S. Madhukar, Varun Vijay Prabhu, Lakshmi Anantharaman, Chidananda Sulli, Edgar Davidson, Sean Deacon, Joseph Rucker, Neil Charter, Benjamin Doranz, Wolfgang Oster, Olivier Elemento, R. Benjamin Free, David Sibley, Joshua E. Allen

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B130; DOI: 10.1158/1535-7163.TARG-17-B130
Abstract B143: The formation of redox active complexes is important for the induction of the UPR by Dp44mT
Angelica Merlot, Nurul Shafie, Georgia Porter, Sumit Sahni, Des Richardson

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B143; DOI: 10.1158/1535-7163.TARG-17-B143

Main menu

User menu

Search

More articles from Therapeutic Agents: Other Topics: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT